|Product Code :||924|
|Availability :||In Stock|
Shipping time 12-14 days.Ask a question
Laferobion - suppositories 10 in pack . One pack
Packaging -10 suppositories in a blister pack. 1 blister pack with 2 blister packs with 5 suppositories in a cardboard box
Composition 1 suppository contains: interferon alpha-2b recombinant human — 150,000 IU or 500,000 IU
Age Children from the very birth
LAFEROBION® suppositories 150,000 MO, suppositories 500,000 MO
for medical use of the drug
active substance: interferon alfa-2b
1 suppository contains: recombinant human interferon alfa-2b - 150,000 IU or 500,000 IU;
excipients: tocopherol acetate 5% butyric solution, ascorbic acid, solid fat.
The main physico-chemical properties: suppositories bullet-shaped yellowish-white color with a homogeneous consistency.
Immunostimulants. Interferons. Interferon alfa-2b.
ATX code L03A B05.
antiviral, antiproliferative and immunomodulating effect.
Interferon alfa-2b recombinant has a pronounced antiviral, antiproliferative and immunomodulating effect. The active substance of the drug Laferobion® - interferon alpha-2b recombinant has an immunomodulating effect on T and B lymphocytes, normalizes the content of immunoglobulin E, and has antiviral activity. Antibodies are not formed that neutralize the antiviral activity of recombinant interferon alpha-2b, even when used for 2 years, the functioning of the endogenous system is normalized.
The pharmacokinetic properties of recombinant interferon alfa-2b have been little studied.
For children: in the complex treatment of acute respiratory viral infections (ARVI).
Hypersensitivity to the components of the drug; the patient has thyroid dysfunction; the presence of severe visceral disorders in patients with Kaposi's sarcoma; severe cardiovascular disease; psoriasis, severe impaired liver and / or kidney function; epilepsy and other diseases of the central nervous system (including functional); chronic hepatitis with progressive or decompensated liver cirrhosis; chronic hepatitis in patients receiving or recently receiving immunosuppressant therapy (except for a short course of corticosteroid therapy); a history of autoimmune hepatitis or other autoimmune diseases. Inhibition of the myeloid germ of hematopoiesis.